A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.
Clin Genitourin Cancer
; 12(3): 167-177.e2, 2014 Jun.
Article
in En
| MEDLINE
| ID: mdl-24365125
Key words
Full text:
1
Database:
MEDLINE
Therapeutic Methods and Therapies TCIM:
Terapias_biologicas
/
Aromoterapia
Main subject:
Carcinoma, Renal Cell
/
Antineoplastic Combined Chemotherapy Protocols
/
Kidney Neoplasms
Language:
En
Journal:
Clin Genitourin Cancer
Year:
2014
Type:
Article